Gene Therapy 13Fs: Vertex-CRISPR, BioMarin, Sarepta, Beam, Editas

US-traded gene therapy equities form a distinctive emerging biotech corner of institutional 13F positioning. Vertex Pharmaceuticals (VRTX, Casgevy with CRISPR Therapeutics), CRISPR Therapeutics (CRSP), BioMarin Pharmaceutical (BMRN, Roctavian), Sarepta Therapeutics (SRPT, Elevidys), Beam Therapeutics (BEAM, base editing), Editas Medicine (EDIT, CRISPR), Intellia Therapeutics (NTLA, in-vivo CRISPR), plus Verve Therapeutics (VERV, in-vivo base editing) anchor the cohort. Multi-year emerging AAV gene therapy adoption, CRISPR gene editing, plus emerging emerging in-vivo gene editing drive distinctive institutional positioning. Reading gene therapy 13F positioning requires understanding the technology framework plus the multi-year clinical dynamics.

The gene therapy business model

Gene therapy companies operate four primary economic engines:

1. AAV gene therapy adoption. Multi-year emerging AAV (adeno-associated virus) gene therapy adoption drives BioMarin plus Sarepta plus emerging emerging emerging Novartis Zolgensma plus emerging emerging Pfizer-Sangamo plus emerging emerging Spark Therapeutics (Roche) operator economics. Multi-year emerging AAV serotype selection plus emerging emerging emerging emerging immunogenicity dynamics plus emerging emerging emerging emerging manufacturing complexity plus emerging emerging emerging emerging premium pricing ($2-3M+ per patient).
2. CRISPR gene editing. Multi-year emerging CRISPR gene editing drives Vertex-CRISPR plus emerging emerging Editas plus emerging emerging Beam plus emerging emerging Intellia plus emerging emerging Verve plus emerging emerging Tessera operator dynamics. Multi-year emerging Vertex-CRISPR Casgevy (sickle cell disease plus beta-thalassemia, FDA approved 2023 first CRISPR therapy at $2.2M per patient) drives multi-year emerging CRISPR commercialization. Multi-year emerging emerging Vertex commercialization plus 50/50 economics CRISPR Therapeutics.
3. In-vivo gene editing. Multi-year emerging in-vivo gene editing drives multi-year emerging operator strategic positioning. Multi-year emerging Intellia NTLA-2001 transthyretin amyloidosis plus emerging emerging Verve VERVE-101 PCSK9 plus emerging emerging Beam BEAM-301 glycogen storage disease plus emerging emerging Prime Editing plus emerging emerging Tessera emerging emerging emerging epigenome editing drive multi-year emerging in-vivo gene editing. Multi-year emerging in-vivo (delivered systemically vs ex-vivo) drives broader patient access.
4. Cell therapy adoption emerging. Multi-year emerging cell therapy adoption drives Gilead-Kite plus emerging emerging Novartis plus emerging emerging Bristol-Myers Squibb plus emerging emerging Johnson & Johnson-Legend Biotech plus emerging emerging 2seventy bio operator dynamics. Multi-year emerging CAR-T (Yescarta, Tecartus, Carvykti, Breyanzi, Abecma) plus emerging emerging T cell engagers plus emerging emerging allogeneic cell therapy plus emerging emerging emerging emerging Adicet plus emerging emerging emerging emerging Allogene drive multi-year cell therapy.

Major US-traded gene therapy names

Vertex Pharmaceuticals (VRTX)

Diversified cystic fibrosis plus emerging emerging Casgevy (CRISPR Therapeutics partnered sickle cell disease plus beta-thalassemia, FDA approved 2023) plus emerging emerging emerging Suzetrigine non-opioid pain plus emerging emerging Type 1 diabetes Zimislecel plus emerging emerging IgA nephropathy povetacicept plus emerging emerging Reshma Kewalramani CEO leadership.

CRISPR Therapeutics (CRSP)

Pure-play CRISPR plus emerging emerging Vertex-partnered Casgevy plus emerging emerging in-vivo CRISPR pipeline plus emerging emerging Samarth Kulkarni CEO leadership.

BioMarin Pharmaceutical (BMRN)

Diversified rare disease plus emerging emerging Roctavian (hemophilia A AAV gene therapy) plus emerging emerging Voxzogo achondroplasia plus emerging emerging Alexander Hardy CEO leadership.

Sarepta Therapeutics (SRPT)

Duchenne muscular dystrophy (DMD) focus plus emerging emerging Elevidys gene therapy (AAV) plus emerging emerging Doug Ingram CEO leadership.

Beam Therapeutics (BEAM)

Base editing pioneer plus emerging emerging ex-vivo plus in-vivo base editing plus emerging emerging BEAM-101 sickle cell disease plus emerging emerging John Evans CEO leadership.

Editas Medicine (EDIT)

CRISPR plus emerging emerging EDIT-301 sickle cell disease plus beta-thalassemia plus emerging emerging Gilead Kite-partnered alpha-beta TCR CAR-T plus emerging emerging Gilmore O'Neill CEO leadership.

Intellia Therapeutics (NTLA)

In-vivo CRISPR pioneer plus emerging emerging NTLA-2001 (transthyretin amyloidosis Phase 3) plus emerging emerging NTLA-2002 hereditary angioedema plus emerging emerging John Leonard CEO leadership.

Verve Therapeutics (VERV)

In-vivo base editing plus emerging emerging VERVE-102 PCSK9 plus emerging emerging Sekar Kathiresan CEO leadership.

How institutional managers position around gene therapy

Three patterns appear across smart-money 13Fs:

Pattern 1: Vertex-Casgevy concentration

VRTX, CRSP-concentrated growth manager positions reflect Casgevy plus emerging emerging CRISPR partnership plus emerging emerging CRISPR commercialization thesis.

Pattern 2: AAV gene therapy positioning

SRPT, BMRN-concentrated growth manager positions reflect AAV gene therapy plus emerging emerging Elevidys plus Roctavian commercialization thesis.

Pattern 3: In-vivo editing positioning

NTLA, VERV-concentrated growth manager positions reflect in-vivo gene editing plus emerging emerging NTLA-2001 plus VERVE-102 thesis.

How to read gene therapy 13F positioning

Three rules apply:

Rule 1: Identify platform exposure

AAV vs CRISPR vs base editing vs in-vivo have distinct dynamics.

Rule 2: Watch clinical readouts

Multi-year clinical trial readouts drive operator pipeline.

Rule 3: Cross-check payer reimbursement

Multi-year payer reimbursement drives operator commercialization.

What gene therapy positioning signals

1. Casgevy conviction. Concentrated VRTX, CRSP positions signal Casgevy plus CRISPR thesis.
2. AAV conviction. Concentrated SRPT, BMRN positions signal AAV gene therapy thesis.
3. In-vivo conviction. Concentrated NTLA, VERV positions signal in-vivo editing thesis.

For real-time tracking of gene therapy 13F activity, see the institutional signals feed.